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Abstract
Background: Type 2 diabetes mellitus (T2D) is a complex disease associated with several chronic complications,
including bone fragility and high fracture risk due to mechanisms not yet fully understood. The influence of the
gastrointestinal tract and its hormones on bone remodeling has been demonstrated in healthy individuals.
Glucagon-like peptide 2 (GLP-2), an enteric hormone secreted in response to nutrient intake, has been implicated
as a mediator of nutrient effects on bone remodeling. This study aimed to analyze the dynamics of bone resorption
marker C-terminal telopeptide of type I collagen (CTX), bone formation marker osteocalcin, and GLP-2 in response
to a mixed meal in diabetic postmenopausal women.
Methods: Forty-three postmenopausal women with osteopenia or osteoporosis (20 controls – group CO – and 23
diabetic – group T2D) were subjected to a standard mixed meal tolerance test, with determination of serum CTX,
plasma osteocalcin and serum GLP-2 concentrations at baseline and 30, 60, 120 and 180 minutes after the meal.
Results: T2D women had higher body mass index as well as higher femoral neck and total hip bone mineral
density. At baseline, luteinizing hormone, follicle-stimulating hormone, osteocalcin and CTX levels were lower in
group T2D. In response to the mixed meal, CTX and osteocalcin levels decreased and GLP-2 levels increased in both
groups. The expected CTX suppression in response to the mixed meal was lower in group T2D.
Conclusions: Bone turnover markers were significantly reduced in T2D women at baseline. Confirming the role of
nutrient intake as a stimulating factor, GLP-2 increased in response to the mixed meal in both groups. Importantly,
CTX variation in response to the mixed meal was reduced in T2D women, suggesting abnormal response of bone
remodeling to nutrient intake in T2D.
Keywords: Bone remodeling, Type 2 diabetes mellitus, Mixed meal, GLP-2, CTX, Osteocalcin
Introduction
Despite high bone mineral density (BMD), studies have
shown that men and women with type 2 diabetes melli-
tus (T2D) are at increased risk for fracture, particularly
nonvertebral fractures [1-6]. Although the pathophysi-
ology of increased bone fragility in individuals with T2D
is not fully understood, several factors such as body
weight, glycemic control and the presence of chronic
complications might contribute [6].
Changes in the rate of bone turnover are an important
determinant of bone disease, and the development of bet-
ter assays has improved the ability of bone turnover
markers to reflect the rate of bone remodeling. Serum
C-terminal telopeptide of type 1 collagen (CTX) is the ref-
erence serum marker for bone resorption, arising from the
degradation of type I collagen in resorbed bone [7]. Osteo-
calcin (OC) is the most abundant non-collagenous protein
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found in bone, being secreted by osteoblasts during oste-
oid synthesis and released into the circulation, providing a
marker for bone formation [8].
Biochemical markers of bone resorption follow a circa-
dian rhythm, rising at night and falling during the day, and
feeding seems to induce this decrease [9-11]. Conversely,
the effects of nutrient intake on bone formation is still a
subject of debate, since some authors describe no variation
[12] or decrease [13] in response to nutrient intake. The
role of the gastrointestinal tract and its hormones, particu-
larly glucagon-like peptide 2 (GLP-2), in bone remodeling
has been recently studied in a variety of clinical settings,
including healthy volunteers, postmenopausal women and
individuals with short bowel syndrome [12,14]. Another
relevant issue is the reciprocal influence between bone
and energy metabolism, that has been described involving
osteocalcin, insulin and leptin [15].
GLP-2 is a 33 amino acid peptide derived from the post
translational processing of glucagon. Biologically active GLP-
21–33 is secreted from the enteroendocrine L cells of the
ileum and colon in response to nutritional, hormonal and
neural stimulation [16]. The main physiological function of
GLP-2 is its trophic action on the bowel mucosa, promoting
its growth and improving its absorptive function [16,17].
More recent data implicate GLP-2 as a mediator of the ef-
fects of nutrition on bone metabolism, particularly on the
suppression of bone reabsorption [12,18,19]. Accordingly,
short-bowel syndrome patients without a colon showed no
reduction in serum concentration of CTX when compared
to normal controls, suggesting that bone resorption is de-
creased postprandially by intestinal factors and GLP-2 is a
possible candidate [19]. In postmenopausal women, exogen-
ous GLP-2 inhibits bone resorption [20], strengthen the evi-
dence that GLP-2 influences bone resorption. No data are
available on the influence of feeding or intestinal factors on
bone remodeling in the context of insulin resistance.
The aim of this study was to assess the effect of a mixed
meal on serum concentrations of bone remodeling
markers OC and CTX and gastrointestinal hormone GLP-
2 in postmenopausal women with T2D and low BMD.
Materials and methods
Study design and subjects
This study comprised postmenopausal women younger
than 65 years of age and with body mass index (BMI)
between 20 and 35 kg/m2 recruited at Hospital das
Clínicas da Faculdade de Medicina da Universidade de
São Paulo, a tertiary center located in the state of São
Paulo, Brazil. Ethical approval was obtained from the
institutional research Ethics Committee of Hospital das
Clínicas da Faculdade de Medicina da Universidade de
São Paulo and participants were only included in the study
following written informed consent. Eligible women
initially underwent a dual-energy x-ray absorptiometry
(DXA) scan of the hip and lumbar spine in addition to
laboratory testing to assess bone and carbohydrate metabol-
ism, including total calcium, phosphorus, parathyroid hor-
mone (PTH), 25-hydroxyvitamin D, serum CTX, plasmatic
OC, 24-hour urinary calcium, besides serum GLP-2. Only
women with low BMD, as defined by current World Health
Organization guidelines as T-scores <−1.0 at either site [21]
were selected for the study. Menopause was defined as the
absence of menstrual cycles for a minimum of four years
confirmed by measurement of follicle-stimulating hormone
(FSH) above 35 mUI/mL and estradiol below 20 pg/mL. Ex-
clusion criteria were as follows: current use of drugs known
to interfere with bone metabolism, current use of hormone
replacement therapy, primary bone diseases with secondary
osteoporosis, kidney failure. Additionally, controle women
were excluded if they had impaired fasting glucose or
glucose intolerance according to American Diabetes Associ-
ation (ADA) criteria [22]. Included participants were allo-
cated to two groups: group T2D, comprising women with
diagnosis of T2D and group CO comprising control women.
All participants were subjected to the mixed meal tolerance
test, as described below. Participants using thiazides or se-
lective serotonin reuptake inhibitors were instructed to
interrupt use of these medications 48 hours prior to the
mixed meal tolerance test.
Mixed meal tolerance test
Following 12-hour overnight fasting, subjects were of-
fered a breakfast-like meal at 8:00 am. Blood samples
were drawn at baseline and 30, 60, 120, and 180 minutes
after the meal. A standard meal was given, composed of
562 kcal corresponding to 51.2% carbohydrates, 33.4%
lipids and 15.4% protein, in addition to 8.2 g of monoun-
saturated fatty acids and 5.2 g of polyunsaturated fatty
acids, and had to be consumed within 15 minutes.
Hormonal determinations
Osteocalcin (OC) was measured using an ELISA (enzyme-
linked immunoabsorbent assay) kit (DIAsource Immuno-
Assays S.A., Belgium) [23,24]; the normal reference range
is 5–25 ng/mL, with an intra-assay variation of 3–5% and
an inter-assay variation of 3.5–5.6%. C-terminal telopep-
tide (CTX) was measured using an ELISA kit (Immuno
Diagnostic Systems Ltd, United Kingdom) [25]; the nor-
mal reference range for postmenopausal women is 0.142–
1.351 ng/mL, with an intra-assay variation of 1.7–3% and
inter-assay variation of 3–11%. GLP-2 was measured using
an ELISA kit (Millipore Corporation, United States)
[26,27] with a standard curve of 1–64 ng/mL, intra-assay
variation of less than 10%, and inter-assay variation of less
than 12%. This assay measures total levels of GLP-2, in-
cluding active [1-33] and inactive [3-33] isoforms.
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Statistical analysis
Statistical analysis was performed using SPSS v15.0, setting
the level of significance was at 0.05. Numerical variables
are expressed as mean ± standard deviation and were com-
pared using Student’s t-test. Percent values were compared
using the chi-square test, and hormonal curves were ana-
lyzed through two-way (time-point and group) analysis of
variance (ANOVA) with repeated measures, followed by
the Tukey’s multiple comparison test when statistically sig-
nificant differences were identified between the groups
[28]. Pearson correlation coefficients were used to assess
the relationship between CTX, OC, GLP-2, BMD and body
mass index (BMI).
Results
Group characteristics and baseline assessment
A total of 43 postmenopausal women with low BMD
(osteoporosis or osteopenia) participated in this study,
comprising 23 women with T2D (group T2D) and 20
controls (group CO). General characteristics of partici-
pants are shown in Table 1. Although the two study
groups were not matched, the participants’ age and the
time since menopause were similar in groups T2D and
CO. The groups differed in BMI, which was greater in
group T2D (30 ± 3.9 vs. 27 ± 5.3 kg/m2, p = 0.044), and
in femoral neck and total hip BMD, which were also
higher in group T2D (Table 1).
Approximately 70% of the participants with diabetes also
had arterial hypertension, and almost half were obese. Both
diseases were less prevalent in group CO (p < 0.05). In group
T2D, the median duration of diabetes was 13.7 ± 9.2 years,
and mean glycated hemoglobin level (HbA1c) was 7.8 ±
1.7%. Among participants with T2D, 47.8% used insulin, and
91.3% used oral hypoglycemic agents. The most prevalent
chronic complication of diabetes was macrovascular disease.
Baseline laboratory testing revealed additional differences
between the groups (Table 2). Mean follicle-stimulating hor-
mone (FSH) and luteinizing hormone (LH) levels were
lower in group T2D compared to CO. Groups CO and T2D
were similar in regard to the following baseline bone metab-
olism parameters: 25-hydroxyvitamin D, total calcium,
phosphorus, PTH (parathyroid hormone), and 24-hour
urinary calcium and phosphate. Baseline CTX and OC
concentrations were lower in participants with T2D
compared to the controls, while GLP-2 concentrations
were similar in both groups (Table 2).
For all 43 participants, BMI had a positive correlation
with hip BMD (p = 0.004; r = 0.444). In group T2D, gly-
cated hemoglobin (HbA1c) levels had no correlation with
BMD values at any assessed sites.
Hormonal response to the mixed meal tolerance test
Serum CTX levels decreased throughout the mixed
meal tolerance test in both groups (p < 0.05) (Figure 1).
Intergroup comparison of test curves detected a statis-
tically significant difference (p = 0.003), which was at-
tributable to higher baseline values in group CO and to
reduced variation of CTX in group T2D throughout the
test (T2D Δ: −0.21 vs. CO Δ: −0.38 ng/mL; p < 0.050)
(Figures 1 and 2).
Following the mixed meal, plasma OC levels decreased
gradually in both groups (p < 0.001). OC levels were lower
in diabetic participants compared to controls in all the
time-points of the meal test. OC response curves were
similar between groups T2D and CO (p = 0.222) (Figure 1).
GLP-2 levels varied throughout the mixed meal tolerance
test in both groups (p < 0.001), increasing from baseline to
time-point 30 minutes and decreasing from time-point
120 minutes onwards (p < 0.05), as shown in Figure 1.
Intergroup comparison of response curves showed that the
Table 1 Baseline characteristics of study participants
Variable Group T2D
(n = 23)
Group CO
(n = 20)
p-value
Mean (SD) Mean (SD)
Age (years) 59.8 (4.2) 57.8 (3.3) 0.087
Time since menopause (years) 9.8 (4.3) 7.4 (4.5) 0.105
Diabetes duration (years) 13.7 (9.2) — —
BMI (kg/m2) 30 (3.9) 27 (5.3) 0.044
Femoral neck BMD (g/cm2) 0.78 (0.09) 0.69 (0.08) 0.003
Total hip BMD (g/cm2) 0.93 (0.09) 0.82 (0.09) <0.001
Lumbar spine BMD (g/cm2) 0.87 (0.09) 0.82 (0.12) 0.17
T2D, type 2 diabetes; CO, control; SD, standard deviation; p-value, Student’s
t-test p-value; BMI, body mass index; BMD, bone mineral density.
Table 2 Baseline laboratory evaluation
Variable Reference
range
Groups T2D
(n = 23)
Group CO
(n = 20)
p-value
Mean (SD) Mean (SD)
FSH (IU/L) 31 to 134 49.7 (16.5) 78.1 (13.4) < 0.001
LH (IU/L) 15 to 64 24.2 (12.4) 36.2 (11.4) 0.012
Estradiol (pg/mL) <25 15.7 (2.7) 17,9 (6.0) 0.15
Total calcium (mg/dL) 8.6 to 10.2 9.6 (0.6) 9.3 (0.6) 0.129
Phosphorus (mg/dL) 2.7 to 4.5 3.9 (0.5) 3.6 (0.5) 0.164
PTH (pg/mL) 16 to 87 45.3 (18.8) 51.1 (17.0) 0.237
25-OHD (ng/mL) 30 to 100 21.3 (8.5) 20.4 (5.2) 0.685
CTX (ng/mL) 0.142 to
1.351
0.49 (0.25) 0.66 (0.22) 0.04
Osteocalcin (ng/mL) 5 to 25 10.2 (5.4) 14.8 (5.3) 0.008
GLP-2 (ng/mL) 1 to 6415 4.1 (2.0) 3.8 (1.8) 0.61
24-hour urinary
calcium (mg/24 h)
100 to 320 174.7 (91.6) 151.9 (63.2) 0.44
T2D, type 2 diabetes; CO, control; SD, standard deviation; p-value, Student’s
t-test p-value; FSH, follicle-stimulating hormone; LH, luteinizing hormone; PTH,
parathyroid hormone; CTX, C-terminal telopeptide of type I collagen; GLP-2,
Glucagon-like peptide 2.
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GLP-2 dynamics were similar in both groups throughout
the test (p > 0.05) (Figure 1).
In all subjects, a significant negative correlation was
found between OC levels at all mixed meal tolerance test
time-points and BMI (p < 0.05, r value ranging from −0.339
to −0.417). Conversely, CTX levels had no correlation with
BMI or BMD. Interestingly, GLP-2 levels had a positive
correlation with total hip and femoral neck BMD at all the
mixed meal tolerance test time-points (p < 0.05, r value ran-
ging from 0.349 to 0.506). Inclusion of BMI as a potential
confounding factor in ANOVA showed that BMI did not
account for the differences in OC and CTX levels observed
between groups T2D and OC.
Discussion
This study aimed to analyze the response of bone re-
modeling markers and gastrointestinal hormone GLP-2
to a mixed meal in postmenopausal women with T2D in
comparison to controls. We show that T2D participants
had lower levels of bone turnover markers at baseline
and, importantly, that the degree of suppression of bone
resorption marker CTX following a mixed meal is re-
duced in diabetic women.
Our study design included a mixed meal tolerance test
to stimulate GLP-2 production, which could potentially
better reflect the effects of nutrient absorption on enteric
hormones on bone remodeling markers than the oral glu-
cose tolerance test [29] or the separate intake of various
nutrients [12]. Besides its well-established role in bowel
mucosa growth and function, GLP-2 has been implicated
as a mediator of nutrient effects on bone resorption.
The analyzed groups were similar in regard to partici-
pants’s age and time since menopause, which are relevant
factors in the study of bone metabolism parameters. Com-
parison of BMD between groups T2D and CO revealed
greater femoral neck and total hip BMD in T2D partici-
pants, which is in agreement with the literature [3-5,30].
Nevertheless, participants with T2D had higher BMI,
which could limit the interpretation of DXA assessment,
since obesity is a well-know confounding factor for BMD
[31]. No correlation was found between HbA1c levels and
BMD among T2D participants, which is disagreement with
the results of prior studies [30], but could be attributable
to the small sample size.
Of note, mean baseline FSH and LH levels were higher
in controls than is T2D participants, even though time
since menopause was similar between groups. Ovarian
function is altered in diabetic women throughout repro-
ductive life and in menopause, as shown by an earlier de-
cline in AMH and inhibin B levels in type 1 diabetes [32].
The dynamics of postmenopausal gonadotropin secretion
are not fully understood, and data of T2D women are
scarce and contradictory [33,34]. FSH has been shown to
Figure 1 Response of CTX, osteocalcin and GLP-2 to the mixed
meal tolerance test. Results (mean and standard error) for controls, in
black, and T2D patients, in red, are shown for CTX (A), osteocalcin (B)
and GLP-2 (C). *Statistically significant variation (p < 0.05 on analysis of
variance – ANOVA) was observed throughout the mixed meal tolerance
test #Significant difference (p < 0.05 on Tukey’s multiple comparison test)
was observed between the groups at baseline.
Figure 2 CTX suppression in response to the mixed meal.
Variation between basal and nadir for controls (black) and T2D
patients (red) are shown (mean and standard error). *Student’s
t-test p-value = 0.006.
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have direct effects on bone remodeling in rodents, inde-
pendent of estrogen levels [35]. Therefore, additional studies
are needed to assess whether changes in the hypothalamic-
pituitary-gonadal axis account for our observation of re-
duced serum FSH levels in diabetic women, and to investi-
gate what effects might be expected on bone metabolism.
Mean baseline levels of bone remodeling markers OC
and CTX were lower in participants with T2D than in
controls, which would indicate that diabetic women had
reduced turnover. The observed relationship between OC
and T2D might be at least partially explained by BMI,
which was higher in group T2D. Indeed, Viljakainen and
colleagues have recently found that the response of vari-
ous bone remodeling markers, including OC and CTX, to
the oral glucose tolerance test was lower among severely
obese individuals in comparison to controls [36]. Until the
relationship between T2D and bone turnover markers is
fully elucidated, therapeutic decision-making based on as-
sessment of these markers (for example, in the treatment
of osteoporosis) should be taken with care in diabetic
individuals.
Serum CTX dynamics in response to the mixed meal
was different in T2D participants in relation to controls,
suggesting that nutrient-dependent suppression of bone
resorption is attenuated in T2D. Indeed, Chailurkit and
colleagues have reported similar findings using the oral
glucose tolerance test [29]. Plasma OC levels decreased
similarly throughout the mixed meal tolerance test in both
groups, however they were persistently lower in T2D sub-
jects. Importantly, body mass index did not seem to influ-
ence the comparison of CTX and OC response between
groups.
Confirming the role of nutrient intake as a stimulating
factor for GLP-2 production [12,14,37], GLP-2 response to
the mixed meal was similar in both groups. Therefore,
based on the results of this study, we cannot ascertain that
GLP-2 is responsible for the abnormal bone remodeling in
T2D. Nevertheless, we found a positive correlation be-
tween GLP-2 and femoral neck and total hip BMD, cor-
roborating a potential influence of this intestinal hormone
on bone metabolism. Further clinical studies are necessary
to clarify the role of GLP-2 in bone metabolism in healthy
and T2D individuals.
Conclusion
We conclude that T2D postmenopausal women have al-
tered bone remodeling at basal conditions and in response
to nutrient intake. Further studies focusing on the influ-
ence of gastrointestinal hormones on bone metabolism
are needed to advance our understanding of bone fragility
in individuals with diabetes.
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